Combined with previous preclinical testing supporting a class effect of MEKi in preclinical models and observations of correlation between pERK1/2 staining and Ki67 expression [22], these data support the basis of the CONNECT 2108 trial (NCT05286788) evaluating Binemetinib in recurrent craniopharyngioma and the use of MAPK inhibitor Tovarafanib (DAY101) T in the PNOC029 trial (NCT05465174). Here, MKI67 is linked to craniopharyngioma.